A Study of QL1706 Combined With Platinum-containing Chemotherapy in Adjuvant Treatment of Stage II-IIIB Non-small Cell Lung Cancer After Complete Surgical Resection.

This study is testing whether adding an immunotherapy drug (QL1706, which targets PD-1 and CTLA-4 checkpoints) to standard platinum-based chemotherapy improves outcomes after surgery for people with Stage II–IIIB non-small cell lung cancer (NSCLC) that has been completely removed. **You may be eligible if...** - You are 18 or older - You have been diagnosed with Stage II–IIIB NSCLC (squamous or non-squamous) confirmed by biopsy - Your cancer was completely removed by surgery (R0 resection) - You are starting adjuvant (post-surgery) treatment within 10 weeks of your operation - If non-squamous: your tumor does not have EGFR mutations or ALK fusions - Your general health status is good (ECOG 0–1) **You may NOT be eligible if...** - You have previously received neoadjuvant or adjuvant chemotherapy or immunotherapy for this cancer - You have HIV, syphilis, or active hepatitis - You have significant cardiovascular, gastrointestinal, or lung problems - You are currently enrolled in another clinical trial Talk to your doctor to see if this trial is right for you.